The following is an excerpt from MedPage Today.
The US Food and Drug Administration (FDA) has issued a warning regarding the use of Veozah (fezolinetant), a hormone-free drug used to treat moderate to severe hot flashes (vasomotor symptoms) in menopausal women. The FDA found a link between the drug and liver damage in patients. Veozah was approved earlier this year, and healthcare providers are now advised to monitor liver function before prescribing and during treatment.
Veozah’s liver damage risks were identified through postmarket reports submitted to the FDA’s Adverse Event Reporting System (FAERS). According to the FDA, a case of liver injury was reported within 40 days of starting treatment.
The FDA now recommends that liver function tests, including ALT, AST, alkaline phosphatase, and total and direct bilirubin, be conducted before initiating treatment and monitored at 1, 3, 6, and 9 months. Patients should stop treatment if they develop fatigue, jaundice, nausea, or upper-right abdominal pain. The drug is contraindicated for patients with severe liver or kidney issues.
Read the FDA’s full communication here.
For the full article, visit MedPage Today here.
NOW AVAILABLE: FOLLOW THE $CIENCE
Order Sharyl Attkisson’s New Bestseller!
Are you going to air interview of with Donald Trump on full measure?
If so when? I really like your show, I don’t miss a single show. I am however am surprised that NBC let’s you.
Melanie,
Re : Root Causes
Is Mr. Trump aware of
Communists’ Step-Wise
Goals—to wreck America ?
http://stateofthenation.co/?p=14620
(( read #1, regarding FDA drugs for
hot flashes ))
-Rick